

# SARS-CoV-2 neutralizing antibody

Catalog No.: A19215 **8 Publications**

## Basic Information

### Observed MW

Refer to figures

### Calculated MW

### Category

Primary antibody

### Applications

< 0.1 EU/μg of the protein by LAL method.

### Cross-Reactivity

### CloneNo number

AHC0005

## Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused COVID-19. This response focuses on the mechanism by which SARS-CoV-2 enters host cells, specifically the binding of the spike(S) protein to its receptor angiotensin-converting enzyme 2 (ACE2) and subsequent membrane fusion. SARS-CoV-2 neutralizing antibodies have been developed for preventive or therapeutic uses. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein1-5 show promise therapeutically. Neutralizing antibodies can block infection, clear pathogens, and are essential to provide long-term immunity. While neutralizing antibodies target the spike protein, their neutralization potency and breadth vary according to recognition epitopes.

## Recommended Dilutions

**Lyophilized from a 0.22 μm filtered solution of PBS**

pH 7.2 with 10% Trehalose.

## Immunogen Information

### Gene ID

Swiss Prot

### Immunogen

Recombinant protein (or fragment). This information is considered to be commercially sensitive.

### Synonyms

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Source

SARS-CoV-2

### Isotype

Human IgG1/kappa

### Purification

>95% as determined by SDS-PAGE

### Storage

Store the lyophilized protein at -20°C to -80 °C for long term.